April 25th 2024
Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
For Patients With Inoperable Stage I NSCLC, Race, Hospital, and Insurance Status Matter
December 2nd 2014Despite the proven benefits of SBRT for patients with inoperable stage I NSCLC, whether such patients are offered it depends on their race, insurance status, and the type of facility where they are being treated.
CMS to Cover Annual Lung Cancer Screening for Some High-Risk Patients
November 14th 2014The Centers for Medicare & Medicaid Services (CMS) announced that the agency plans to cover lung cancer screening using low-dose computed tomography (LDCT) for certain former and current smokers, a decision that could affect an estimated 4 million people.
Moving Proactively to Manage AEs With Targeted Lung Cancer Therapies
November 5th 2014At the 2014 Multidisciplinary Symposium in Thoracic Oncology in Chicago, Jyoti D. Patel, MD, associate professor in Medicine-Hematology/Oncology at the Feinberg School of Medicine at Northwestern University, led a breakout session on how to manage the toxicities associated with the molecular therapies used to treat patients with lung cancers.
Case-Based, Weekly Tumor Boards May Improve Survival and Boost Clinical Trial Participation
October 14th 2014Patients with certain lung and colorectal cancers whose physicians participated in weekly, treatment-focused tumor board meetings had improved survival and were 60% more likely to enroll in a clinical trial
A Spoonful of Honey? New Findings Shed Light on Its Role in Relieving Esophagitis Pain
September 19th 2014New patient-reported data presented at the 2014 ASTRO Annual Meeting has shown that Manuka honey is not more effective than standard medical care for the treatment of esophagitis pain during radiation therapy.
Many Benefits Seen With CT Lung Cancer Screening for Those at High Risk
August 7th 2014When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population.
Addario Lung Cancer Medical Institute Launches New Study, Featured on ABC News
August 5th 2014The Addario Lung Cancer Medical Institute (ALCMI) today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often are athletic, never smokers and do not exhibit any of the known lung cancer genetic mutations.
Ambitious Lung-MAP Trial Launched With Five Novel Drugs
August 1st 2014Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial, an innovative biomarker-driven study that aims to improve the drug development process while exploring therapeutic options for this challenging malignancy.
New Oral Agent Found Effective in Preventing Muscle Wasting in NSCLC
July 1st 2014The results of two phase III trials reported at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer have found that enobosarm, a first-in-class, nonsteroidal, oral selective androgen receptor modulator (SARM), led to an increase in lean body mass (LBM) compared with a decline in LBM observed with placebo for patients with non-small cell lung cancer (NSCLC).
Lung Cancer Treatment Challenges and Opportunities
May 6th 2014Leading experts in the rapidly evolving field of lung cancer treatment assembled for the 1st Annual Miami Lung Cancer Conferenceâ„¢ in Miami Beach, Florida, on March 8, to offer their perspectives on the latest research and provide clinical insights for practitioners dealing with challenging cases.
ALK-Positive Criteria for Determining Crizotinib Use May Fall Short
February 20th 2014The criteria that are presently used to determine whether patients with non-small cell lung cancer (NSCLC) may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug, researchers report.